Cargando…

Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review

Ipilimumab plus nivolumab therapy is approved for patients with unresectable advanced esophageal squamous cell carcinoma (ESCC). Although a combination of immune checkpoint inhibitors (ICIs), compared to conventional chemotherapy, can improve overall survival in patients with advanced ESCC, this inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Hajime, Shionoya, Aika, Arihara, Yohei, Hayasaka, Naotaka, Kubo, Tomohiro, Usami, Makoto, Sugita, Shintaro, Uhara, Hisashi, Takada, Kohichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518453/
https://www.ncbi.nlm.nih.gov/pubmed/37753079
http://dx.doi.org/10.3389/fimmu.2023.1259071
_version_ 1785109517202096128
author Nakamura, Hajime
Shionoya, Aika
Arihara, Yohei
Hayasaka, Naotaka
Kubo, Tomohiro
Usami, Makoto
Sugita, Shintaro
Uhara, Hisashi
Takada, Kohichi
author_facet Nakamura, Hajime
Shionoya, Aika
Arihara, Yohei
Hayasaka, Naotaka
Kubo, Tomohiro
Usami, Makoto
Sugita, Shintaro
Uhara, Hisashi
Takada, Kohichi
author_sort Nakamura, Hajime
collection PubMed
description Ipilimumab plus nivolumab therapy is approved for patients with unresectable advanced esophageal squamous cell carcinoma (ESCC). Although a combination of immune checkpoint inhibitors (ICIs), compared to conventional chemotherapy, can improve overall survival in patients with advanced ESCC, this increases the incidence of immune-related adverse events (irAEs). Here, we describe an ESCC case that developed pemphigus vulgaris (PV), an extremely rare cutaneous irAE, during ipilimumab plus nivolumab treatment. The patient achieved a partial response to treatment. The PV was successfully managed after the cessation of ipilimumab and the use of a topical steroid. We should thus re-treat ESCC with nivolumab monotherapy. In the era of ICIs as standard cancer therapeutics, diagnostic criteria for blistering diseases need to be established to properly manage patients with cutaneous irAEs.
format Online
Article
Text
id pubmed-10518453
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105184532023-09-26 Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review Nakamura, Hajime Shionoya, Aika Arihara, Yohei Hayasaka, Naotaka Kubo, Tomohiro Usami, Makoto Sugita, Shintaro Uhara, Hisashi Takada, Kohichi Front Immunol Immunology Ipilimumab plus nivolumab therapy is approved for patients with unresectable advanced esophageal squamous cell carcinoma (ESCC). Although a combination of immune checkpoint inhibitors (ICIs), compared to conventional chemotherapy, can improve overall survival in patients with advanced ESCC, this increases the incidence of immune-related adverse events (irAEs). Here, we describe an ESCC case that developed pemphigus vulgaris (PV), an extremely rare cutaneous irAE, during ipilimumab plus nivolumab treatment. The patient achieved a partial response to treatment. The PV was successfully managed after the cessation of ipilimumab and the use of a topical steroid. We should thus re-treat ESCC with nivolumab monotherapy. In the era of ICIs as standard cancer therapeutics, diagnostic criteria for blistering diseases need to be established to properly manage patients with cutaneous irAEs. Frontiers Media S.A. 2023-09-11 /pmc/articles/PMC10518453/ /pubmed/37753079 http://dx.doi.org/10.3389/fimmu.2023.1259071 Text en Copyright © 2023 Nakamura, Shionoya, Arihara, Hayasaka, Kubo, Usami, Sugita, Uhara and Takada https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Nakamura, Hajime
Shionoya, Aika
Arihara, Yohei
Hayasaka, Naotaka
Kubo, Tomohiro
Usami, Makoto
Sugita, Shintaro
Uhara, Hisashi
Takada, Kohichi
Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
title Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
title_full Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
title_fullStr Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
title_full_unstemmed Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
title_short Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
title_sort pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518453/
https://www.ncbi.nlm.nih.gov/pubmed/37753079
http://dx.doi.org/10.3389/fimmu.2023.1259071
work_keys_str_mv AT nakamurahajime pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview
AT shionoyaaika pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview
AT ariharayohei pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview
AT hayasakanaotaka pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview
AT kubotomohiro pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview
AT usamimakoto pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview
AT sugitashintaro pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview
AT uharahisashi pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview
AT takadakohichi pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview